Abstract-Prostaglandin (PG) E 2 is an important modulator of the actions of angiotensin (Ang) II. In the present study, we investigated the renal microvascular actions of PGE 2 and the EP receptor subtypes involved. Ibuprofen potentiated Ang II-induced vasoconstriction in in vitro perfused normal rat kidneys and augmented afferent arteriolar, but not efferent arteriolar, responses in the hydronephrotic rat kidney model. This preglomerular effect of endogenous prostanoids was mimicked by exogenous PGE 2 , which reversed Ang II-induced afferent arteriolar vasoconstriction at concentrations of 0.1 to 10 nmol/L without affecting the efferent arteriole. The PGE 2 -induced vasodilation was potentiated by the phosphodiesterase inhibitor Ro 20-1724 and was mimicked by 11-deoxy-PGE 1 (0.01 to 1 nmol/L). Butaprost, which acts preferentially at EP 2 receptors, was relatively ineffective. Key Words: receptors Ⅲ microcirculation Ⅲ arterioles Ⅲ cyclooxygenase Ⅲ angiotensin II P rostaglandin (PG) E 2 is the major prostanoid produced by the kidney and plays an important role in modulating the renal microvascular response to vasoconstrictors. 1 During conditions associated with low renal perfusion pressure, elevated renin activity, and increased renal sympathetic traffic, normal renal function may depend on the modulatory actions of PGE 2 on angiotensin (Ang) II-and catecholamineinduced renal vasoconstriction. In clinical settings such as congestive heart failure, interference with this compensatory mechanism by the administration of nonsteroidal antiinflammatory agents can lead to a deterioration of renal function and renal insufficiency. 2 It has now been disclosed that the diverse biological actions of PGE 2 are mediated by specific members of a group of G protein-linked (EP) receptors (reviewed in Reference 3). Thus, future therapies may allow a more selective intervention based on the development of selective receptor antagonists capable of blocking undesirable effects of the prostanoids while preserving their renal protective actions. This approach will require information on the renal microvascular actions of PGE 2 and the identification of the specific EP receptor subtypes involved.
P rostaglandin (PG) E 2 is the major prostanoid produced by the kidney and plays an important role in modulating the renal microvascular response to vasoconstrictors. 1 During conditions associated with low renal perfusion pressure, elevated renin activity, and increased renal sympathetic traffic, normal renal function may depend on the modulatory actions of PGE 2 on angiotensin (Ang) II-and catecholamineinduced renal vasoconstriction. In clinical settings such as congestive heart failure, interference with this compensatory mechanism by the administration of nonsteroidal antiinflammatory agents can lead to a deterioration of renal function and renal insufficiency. 2 It has now been disclosed that the diverse biological actions of PGE 2 are mediated by specific members of a group of G protein-linked (EP) receptors (reviewed in Reference 3). Thus, future therapies may allow a more selective intervention based on the development of selective receptor antagonists capable of blocking undesirable effects of the prostanoids while preserving their renal protective actions. This approach will require information on the renal microvascular actions of PGE 2 and the identification of the specific EP receptor subtypes involved.
Although PGE 2 is recognized to play a critical role in modulating renal vasoconstriction, the actions of PGE 2 on the renal arterioles have not been thoroughly investigated. Only 2 studies to date have directly examined the renal microvascular actions of PGE 2 . In a study of isolated rabbit arterioles, Edwards 4 reported that PGE 2 elicited afferent arteriolar vasodilation but had no effect on the efferent arteriole. No constrictor responses to PGE 2 were observed in this study. In contrast, Inscho et al, 5 using the blood-perfused juxtamedullary nephron preparation, found 1.0 mol/L PGE 2 to evoke afferent arteriolar vasoconstriction in the rat. Only 1 concentration was used, and the effects of PGE 2 on the efferent arteriole were not examined. Neither study examined the EP receptor subtypes or signaling pathways involved.
At least 4 distinct genes encoding for 4 separate subtypes of PGE 2 receptors, EP 1 to EP 4 (reviewed in Reference 3), have been identified. The mRNA for all 4 EP receptor subtypes has been reported to be expressed in the kidney. 6 -9 EP 2 and EP 4 receptors are generally associated with smooth muscle relaxation, whereas EP 1 and EP 3 receptors are reported to elicit smooth muscle contractile responses. However, although the receptor subtypes involved in the tubular epithelial actions of PGE 2 have been partially characterized (reviewed in Reference 10), we know little of the EP receptor subtypes and signaling pathways involved in the renal microvascular actions of PGE 2 . In the present study, we used the in vitro perfused normal rat kidney and the in vitro perfused hydronephrotic rat kidney models to investigate the actions of PGE 2 on the afferent and efferent arterioles. We used reverse transcription-polymerase chain reaction (RT-PCR) assays of microdissected vessels to determine EP receptor subtype expression in the renal afferent arteriole. Our findings indicate that PGE 2 exerts a selective effect on the afferent arteriole, eliciting both vasodilation and vasoconstriction of this vessel. The vasodilation appears to be mediated by the EP 4 receptor coupled to a cAMP-dependent mechanism. The vasoconstrictor actions of PGE 2 are mediated by an EP 3 receptor coupled to G ␣i and appear to involve a functional antagonism of the EP 4 -induced vasodilation.
Materials and Methods

In Vitro Perfused Hydronephrotic Kidney
Male Sprague-Dawley rats were used in all experiments. The in vitro hydronephrotic rat kidney 11 was used to examine the afferent and efferent arteriolar actions of PGE 2 . Unilateral hydronephrosis was induced by ligating the left ureter. Kidneys were harvested after 6 weeks, when tubular atrophy allows a direct visualization of the renal microvasculature. The renal artery was cannulated, and the kidney was excised with continuous perfusion. Kidneys were perfused at a renal arterial pressure of 80 mm Hg, with a modified Dulbecco's medium containing 30 mmol/L bicarbonate, 5 mmol/L glucose, and 5 mmol/L HEPES and equilibrated with 95% air/5% CO 2 (37°C, pH 7.4). Diameters were measured by online image processing. Afferent diameters were measured between the midpoint and origin. Efferent arteriolar diameters were measured within 50 m of the glomerulus.
Initial studies were performed to determine the effects of basal prostaglandins. In all subsequent studies, kidneys were pretreated with 10 mol/L ibuprofen to eliminate endogenous prostanoids. PGE 2 was obtained from Calbiochem and prepared fresh daily. Ro 20-1724 was obtained from Research Biochemicals International and was administered at 0.5 mol/L. Sulprostone and 11-deoxy-PGE 1 were obtained from Cayman Chemical Co. Butaprost was provided by Dr Kluender of Bayer Pharmaceutical Division. SC-51322 was obtained from BIOMOL Research Laboratories.
In Vitro Perfused Normal Kidney
For the normal kidney studies, rats weighing from 220 to 275 g were anesthetized with methoxyflurane. The left renal artery was cannulated in situ, and the kidney was excised with continuous perfusion. Kidneys were perfused in vitro at 80 mm Hg as described above. Perfusate flow was measured with a transonic flowmeter (model T106, Transonic Systems, Inc).
EP mRNA Expression in Isolated Afferent Arterioles
Normal kidneys were perfused with 2% agarose (37°C in DMEM) and chilled (4°C). Cortical slices (400 m) were prepared and treated with collagenase IV, hyaluronidase IV, dispase II, and DNAse I. Six to 8 arterioles were individually isolated and washed 3 times. RT-PCR was run on the final wash to test for contamination. Arteriolar total RNA was extracted, and cDNA was synthesized with random primers. To eliminate genomic contamination, a separate sample was treated identically, but without reverse transcriptase ( Figure 8A and 8B). Primers for RT-PCR assays were designed from the reported EP receptor sequences [12] [13] [14] [15] [16] [17] (Table 1 online, see http:// www.circresaha.org). We assayed for a sequence common to all EP 3 receptors (EP 3␣␤␥ ) and sequences specific for EP 1 , EP 2 , EP 4 , and each EP 3 splice variant. A whole-kidney homogenate was used as a positive control, and primers for GAPDH 18 were used for an internal control. After 35 cycles, PCR products were separated by electrophoresis (2% agarose gel) and stained with ethidium bromide. The identity of the products obtained with each set of primers was confirmed by DNA sequencing. When negative results were obtained, fresh polymerase was added after 35 cycles, and the PCR was continued to 70 cycles.
Analysis
Data are expressed as the meanϮSEM. Differences were evaluated by ANOVA and Student's t test (paired or unpaired). Values of PϽ0.05 were considered significant. For multiple comparisons, the Bonferroni correction was applied, and values of PϽ0.05/n were considered significant.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Initial studies were conducted to determine the influence of endogenous prostaglandins on Ang II responses of the in vitro perfused hydronephrotic kidney preparation and of in vitro perfused normal rat kidneys. The effects of 10 mol/L ibuprofen on the afferent and efferent arteriolar actions of Ang II are presented in Figure 1A . Basal diameters were not affected by ibuprofen in either the afferent (15 Figure 1A , ibuprofen pretreatment resulted in significant potentiation of the afferent arteriolar response at Ang II concentrations of 0.01 to 0.1 nmol/L (PϽ0.05). In contrast, the efferent arteriolar response to Ang II was not significantly altered by ibuprofen, and 0.03 nmol/L Ang II elicited significant efferent arteriolar vasoconstriction in both settings.
Ibuprofen also potentiated Ang II-induced vasoconstriction in normal perfused rat kidneys ( Figure 1B ). In the control group, basal perfusate flows were 14.6Ϯ0.9 mL ⅐ min Ϫ1 ⅐ g kidney wt Ϫ1 (nϭ5), and Ang II elicited significant vasocon-
.0001). In kidneys pretreated with 10 mol/L ibuprofen, basal perfusate flows were 13.4Ϯ0.6 mL ⅐ min Ϫ1 ⅐ g Ϫ1 (Pϭ0.26 versus control, nϭ5) and Ang II elicited significant vasoconstriction at 0.03 nmol/L (11.8Ϯ0.5 mL ⅐ min Figure 1B , ibuprofen significantly potentiated the vasoconstrictor response to Ang II at concentrations of 0.03 and 0.1 nmol/L (PϽ0.05). In concert, the findings presented in Figures 1A and 1B illustrate that the threshold for Ang II-mediated vasoconstriction occurs over similar concentrations in the in vitro perfused hydronephrotic kidney and normal kidney preparation and that cyclooxygenase inhibition potentiates reactivity to Ang II in both models.
Pϭ0.0036). As presented in
Because the major prostanoid produced by the kidney is PGE 2 , we examined the effects of exogenous PGE 2 on the afferent and efferent arteriolar response to Ang II. In these studies and those that follow, kidneys were pretreated with 10 mol/L ibuprofen to eliminate endogenous prostanoid formation. As shown in Figure 2 , 0.1 nmol/L Ang II reduced afferent arteriolar diameter by 43Ϯ7% (nϭ8) and efferent arteriolar diameter by 23Ϯ5% (nϭ7, PϽ0.001). PGE 2 exerted a biphasic action on the afferent arteriole. Over concentrations ranging from 1 to 10 nmol/L, PGE 2 elicited afferent arteriolar vasodilation, completely reversing the Ang IIinduced vasoconstriction. At concentrations Ͼ100 nmol/L, PGE 2 elicited vasoconstriction. Thus, whereas PGE 2 completely reversed Ang II-induced vasoconstriction at a concentration of 10 nmol/L (14.2Ϯ0.6, 8.2Ϯ1.2,* and 13.4Ϯ0.7 m for control, Ang II, and Ang II plus 10 nmol/L PGE 2 , respectively; *PϽ0.05 versus control), increasing the PGE 2 concentration to 1.0 mol/L fully restored the vasoconstriction (7.0Ϯ1.4 m, PϾ0.05 versus Ang II alone). In the absence of Ang II (Figure 2 , top), PGE 2 also elicited a modest vasodilation and constriction at concentrations of 10 nmol/L and 1 mol/L (PϽ0.05). However, the constrictor actions of PGE 2 (1.0 mol/L) were far greater in the presence of Ang II (51Ϯ8% decrease in diameter) than in its absence (11Ϯ3% decrease). Finally, in contrast to the afferent arteriole, the efferent arteriolar actions of Ang II were not significantly altered by PGE 2 over concentrations ranging from 1.0 nmol/L to 1.0 mol/L (Figure 2, bottom) .
To investigate the signaling pathway involved in the vasodilation, we determined the effects of the specific type IV phosphodiesterase inhibitor Ro 20-1724. A concentration of 0.5 mol/L Ro 20-1724 was selected for these studies because we found that this concentration does not produce vasodilation by itself but rather potentiates the vasodilatory actions of adenosine (not shown). Two groups of hydronephrotic kidneys (controls and Ro 20-1724 -treated, nϭ5 for each) were preconstricted with 0.1 nmol/L Ang II, and the afferent arteriolar vasodilatory actions of PGE 2 were assessed. The inhibition of the Ang II-induced vasoconstriction was calculated, and these data are summarized in Figure 3 . Ro 20-1724 markedly potentiated the actions of PGE 2 , shifting the ED 50 by Ϸ1 log unit. These findings are consistent with the currently held view that the vasodilatory actions of PGE 2 are mediated by cAMP.
Both EP 2 and EP 4 have been shown to be coupled to G ␣s and are thought to produce vasodilation by stimulating the production of cAMP. 3 To characterize the receptor involved in the afferent arteriolar vasodilation, we compared the potency of 11-deoxy-PGE 1 and butaprost. These 2 agonists have similar affinities for the EP 2 receptor but markedly different affinities for the EP 4 receptor. 13, 19 Figure 4 summarizes the results of studies comparing the actions of these 2 agonists on afferent arterioles preconstricted with 0.1 nmol/L Ang II (nϭ5 for both groups). As depicted, 11-deoxy-PGE 1 fully reversed Ang II-induced afferent arteriolar vasoconstriction (ED 50 Ϸ0.1 nmol/L). In contrast, butaprost was a relatively weak vasodilator in this preparation. These results are consistent with an EP 4 -mediated vasodilation. 3,13,19 -21 The biphasic response of the afferent arteriole to PGE 2 indicates actions at multiple receptor subtypes, linked to both vasodilator and vasoconstrictor mechanisms. To characterize the constrictor response, we examined the effects of pretreatment with pertussis toxin (PTX). In these studies, kidneys were pretreated with 200 g/mL PTX for 1 hour with a recirculating circuit. Control kidneys were treated in an identical manner with vehicle alone. The kidneys were then returned to the single-pass perfusion system and challenged with Ang II and PGE 2 . As shown in Figure 5 , PTX had no effect on the magnitude of the Ang II-induced vasoconstriction and did not alter the vasodilatory actions of 10 nmol/L PGE 2 . However, PTX treatment completely abolished the vasoconstrictor actions of 1.0 mol/L PGE 2 .
Of the known PGE 2 receptors, the EP 3 receptor subtype has been shown to be coupled to the PTX-sensitive G protein G ␣i . 3 We next examined the effects of the EP 3 /EP 1 receptor agonist sulprostone. 3, 22 As shown in Figure 6A , sulprostone did not elicit afferent arteriolar vasodilation in kidneys preconstricted with Ang II and, in this setting, had no vasoconstrictor activity. However, as described above (Figure  2 ), the vasoconstrictor actions of PGE 2 were much more evident when administered to preconstricted vessels that were then dilated with low concentrations of PGE 2 . We therefore designed studies to mimic this condition, first inducing vasoconstriction with Ang II, then eliciting full vasodilation with 10 nmol/L PGE 2 , and then administering sulprostone ( Figure 6B ). Under these conditions, sulprostone caused a dose-dependent vasoconstriction, eliciting threshold contractions at concentrations of 1.0 to 10 nmol/L. Because sulprostone can activate both EP 1 and EP 3 , we examined the effects of SC-51322, an EP 1 -selective antagonist (pA 2 ϭ8.1), 23 on this response. As shown in Figure 1 online (see http:// www.circresaha.org), SC-51322 at concentrations of 3 and 10 mol/L had no effect on the sulprostone-induced vasoconstriction, suggesting that this response is mediated by EP 3 receptors.
The results of the above studies suggest that an EP 3 receptor coupled to a PTX-sensitive G protein mediates the afferent arteriolar vasoconstrictor effects of PGE 2 in the hydronephrotic kidney model. To determine whether a similar response occurs in the nonhydronephrotic kidney, parallel studies were performed using isolated perfused normal kidneys. Kidneys were treated with 10 mol/L ibuprofen and perfused at a constant arterial pressure of 80 mm Hg. Vaso- constriction was established with 0.1 nmol/L Ang II, and then 10 nmol/L PGE 2 was administered. As depicted in Figure 7 , PGE 2 partially reversed the Ang II-induced vasoconstriction, consistent with a selective afferent arteriolar vasodilation. In this setting, sulprostone elicited a similar vasoconstrictor response.
Finally, to determine the expression of EP receptors in the renal afferent arteriole, RT-PCR was used to assay EP receptor mRNA in individually isolated afferent arterioles. As depicted in Figure 8A , the presence of afferent arteriolar message for EP 3 (EP 3␣␤␥ ) and EP 4 receptors, but not for EP 1 or EP 2 receptors, could be demonstrated with this approach. To further identify the EP 3 receptors present, individual primers for mRNA regions specific for the ␣, ␤, and ␥ splice variants were used. As shown in Figure 8B , we found the mRNA for all 3 splice variants to be expressed in the normal afferent arteriole.
Discussion
The diverse actions of PGE 2 on the kidney are mediated by a distinct group of G protein-coupled receptors. Four genes encoding for differing PGE 2 receptors have been cloned (EP 1 to EP 4 ), and message for all 4 receptor subtypes is found in the kidney. 6 -10,24 Previous studies have focused on the EP receptors mediating the renal tubular actions of PGE 2 , but no information is currently available on the renal microvascular EP receptors. The present study indicates that the afferent arteriole of the rat expresses message for the EP 4 receptor and for 3 known splice variants of the EP 3 receptor (␣, ␤, and ␥). We found PGE 2 to elicit vasodilation at low concentrations (ED 50 Ͻ3 nmol/L) by activating EP 4 receptors coupled to cAMP. This vasodilation is reversed at higher concentrations (Ͼ100 nmol/L). This vasoconstrictor response is mediated by an EP 3 receptor coupled to G ␣i and reflects a functional antagonism of the EP 4 -mediated vasodilation.
The present study used the hydronephrotic rat kidney model to assess microvascular responses. Although this model is a widely used method of studying the renal microvasculature, it was important to characterize the role of endogenous prostanoids in this preparation. During the onset of hydronephrosis, infiltrating macrophages increase renal thromboxane production, eliciting vasoconstriction. 25, 26 For microvascular studies, a long-term preparation (6 to 8 weeks' duration) is used. At this stage, tubular atrophy is complete, renal thromboxane production returns to normal levels, 27 and SQ29548 has no effect on basal tone, indicating a lack of thromboxane-dependent vasoconstriction. 28 The reactivity of our in vitro model to Ang II was similar to that of the normal kidney, because threshold vasoconstrictor responses were observed at concentrations of 0.03 to 0.1 nmol/L in both preparations. Moreover, the reactivity to Ang II was similarly potentiated by cyclooxygenase inhibition, suggesting a predominant influence of endogenous vasodilatory prostanoids in both models ( Figure 1A and 1B) .
Cyclooxygenase inhibition potentiated the afferent arteriolar actions of Ang II but had no effect on the efferent arteriole, indicating a selective preglomerular action of en- (Table 1 online, see http://www. circresaha.org). Lane 5 is the internal control (GAPDH). Lane 6 is a positive control using mRNA from kidney homogenate (EP 1 and EP 2 only). Afferent arteriolar message for EP 3 (EP 3␣,␤,␥ ) and EP 4 receptors was clearly demonstrated (panels 3 and 4 from top). In contrast, we could not demonstrate mRNA for the EP 1 (panel 1) or EP 2 (panel 2) receptors in the afferent arteriole. B, Afferent arteriole expressed mRNA for all 3 isoforms of the EP 3 receptor. Lane 1 is 100-bp ladder. Lanes 2 and 3 are the negative controls (no reverse transcriptase and final wash of arteriole isolation, respectively). Lane 4 is the internal control (GAPDH on arterioles). Lanes 5, 6, and 7 are RT-PCR products using the EP 3␣ , EP 3␤ , and EP 3␥ primers (Table 1 online, see http://www. circresaha.org), respectively.
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dogenous prostanoids in our model. These findings are consistent with previous observations using in vivo preparations. For example, Heller and Horacek 29 and Olsen et al 30 found that cyclooxygenase inhibition potentiates the ability of Ang II to reduce glomerular filtration rate in the dog. These authors suggested a protective role of vasodilatory prostanoids in suppressing Ang II-mediated afferent arteriolar vasoconstriction. Our results are in agreement with this interpretation and suggest that the prostanoid involved in this action is PGE 2 , the major prostanoid produced by the normal kidney 1,2 and by cortical interstitial cells of the hydronephrotic kidney. 26 Like the endogenous prostanoid, exogenous PGE 2 altered the afferent arteriolar effects of Ang II but had no effect on the efferent arteriole. This selective afferent arteriolar effect of PGE 2 observed in our rat kidney model agrees with previous findings by Edwards, 4 who used isolated afferent and efferent arterioles from the rabbit. Edwards reported PGE 2 to block the afferent arteriolar response to norepinephrine but to have no effect on the efferent arteriolar actions of either norepinephrine or Ang II. Ang II does not constrict the afferent arteriole in Edwards' preparation. 31 At concentrations Ͼ100 nmol/L, we found PGE 2 to promote afferent arteriolar vasoconstriction. A number of previous studies have documented both vasodilator and vasoconstrictor actions of PGE 2 (reviewed in Reference 1). Edwards did not observe PGE 2 -induced vasoconstriction in isolated rabbit arterioles. 4 However, in a study using the bloodperfused juxtamedullary nephron preparation of the rat, Inscho et al 5 found PGE 2 to elicit afferent arteriolar vasoconstriction. In the Inscho study, only a single concentration of PGE 2 (1.0 mol/L) was used, and efferent arteriolar responses were not reported. Our observation that 1.0 mol/L PGE 2 elicited afferent arteriolar vasoconstriction in the hydronephrotic kidney model is consistent with these findings. The fact that PGE 2 elicits both constrictor and dilator responses clearly indicates an involvement of multiple EP receptor subtypes. EP 2 and EP 4 receptors are both linked to vasodilation (reviewed in Reference 3). Our studies indicate that in the afferent arteriole, PGE 2 elicits vasodilation by activating EP 4 receptors. In this vessel, we found 11-deoxy-PGE 1 to be a potent vasodilator, whereas butaprost was relatively ineffective (Figure 4 ). Butaprost and 11-deoxy-PGE 1 are both EP 2 agonists and exhibit similar potencies at this receptor subtype. 13, 19 However, 11-deoxy-PGE 1 is also a potent EP 4 agonist, whereas butaprost has very weak activity at this receptor. 3,13,19 -21 Thus, the rank order of potencies we observed (11-deoxy-PGE 1 Ͼ Ͼ butaprost) suggests that the vasodilation involves the EP 4 rather than the EP 2 receptor. This interpretation is consistent with the results of our RT-PCR studies, in that we found that message for EP 4 but not EP 2 was expressed in the afferent arteriole. We could not demonstrate the presence of EP 2 mRNA even under extreme conditions (70 cycles). Previous studies have reported low expression levels of EP 2 mRNA in the kidney and an absence of this signal in the renal cortex. 6 We also found low levels of EP 2 mRNA in whole-kidney homogenates ( Figure 8A ). In contrast, EP 4 receptor mRNA is highly expressed in the kidney and has been localized to the glomerulus. 6, 7 Both EP 2 and EP 4 receptors have been shown to be coupled to G ␣s and stimulation of adenylyl cyclase (reviewed in Reference 3). The phosphodiesterase inhibitor Ro 20-1724 potentiated the vasodilatory response to PGE 2 in our study, a finding in agreement with previous observations suggesting that the renal microvascular actions of PGE 2 are mediated by an elevation in cAMP. 1, 32 Our observations are thus consistent with a signaling pathway involving PGE 2 stimulation of EP 4 receptors, leading to the activation of G ␣s , adenylyl cyclase, and vasodilation via cAMP-dependent mechanisms.
Our studies suggest that the vasoconstrictor actions of PGE 2 involve an EP 3 receptor. Sulprostone caused vasoconstriction at concentrations of 10 to 100 nmol/L, whereas constrictor responses to PGE 2 occurred only at much higher concentrations (0.3 to 1.0 mol/L). Sulprostone acts on both EP 1 and EP 3 receptors but is less potent than PGE 2 on EP 1 receptors and more potent on EP 3 receptors. 3, 13, 20 The relative potency of sulprostone versus PGE 2 is thus consistent with an EP 3 response. This interpretation is supported by our observation that SC53122, an EP 1 -selective antagonist, did not alter the vasoconstrictor response to sulprostone. The RT-PCR studies are also consistent with an involvement of EP 3 rather than EP 1 receptors, because we found that the afferent arteriole expresses message for all 3 splice variants of the rat EP 3 receptor, but we could not demonstrate message for EP 1 in this vessel. Finally, the contractile response to PGE 2 was prevented by PTX, indicating a coupling to G ␣o or G ␣i . EP 1 -mediated responses are insensitive to PTX and generally linked to G ␣q , whereas G ␣i coupling is a common characteristic of EP 3 receptors. 3, 33 In concert, these observations provide compelling evidence that the EP 3 receptor mediates PGE 2 -induced afferent arteriolar vasoconstriction.
Thus, our functional studies indicate that in the rat, the renal microvascular actions of PGE 2 are mediated by EP 4 and EP 3 receptors. We found no evidence for the expression of EP 1 or EP 2 receptors in the rat afferent arteriole. In contrast, Morath et al 24 recently reported that in the human kidney, the afferent arteriole stains positively for all 4 EP receptor subtypes. One obvious explanation of this difference is the possibility of species-dependent variability in EP receptor expression. Another possibility is that EP 1 and EP 2 mRNAs are present, but at levels that were below the detection limits in our assay. However, we found the pharmacological attributes of the responses we observed to be consistent with the results of the RT-PCR assays in that each approach suggested a primary role of EP 4 and EP 3 receptors.
We found message for all 3 known splice variants of the rat EP 3 receptor in the rat afferent arteriole. The variable region of the EP 3 receptor subtypes is confined to the intracellular carboxylic tail and determines G protein coupling. 34 Because the sequence is identical from the amino-terminus through the seventh transmembrane domain, including the external portion of the receptor, the EP 3 ␣, ␤, and ␥ isoforms are thought to have similar ligand-binding characteristics. 3 All 3 rat EP 3 receptor isoforms can couple to G ␣i . EP 3␥ can also couple to G ␣s and can stimulate adenylyl cyclase. 3, 16, 34 However, sulprostone had no vasodilatory effect on the afferent arteriole (Figure 6 ), which argues against a role of EP 3␥ receptors in the PGE 2 -induced afferent arteriolar vasodilation. A fourth vari-ant, EP 3␦ , is coupled to a PTX-insensitive G ␣q . 3, 34 However, to the best of our knowledge, this splice variant has not yet been found in the rat.
Although the role of the vasodepressant action of PGE 2 is widely appreciated, the significance of the PGE 2 -induced vasoconstriction is not understood. In our study, PGE 2 elicited a pronounced vasoconstriction in the presence of Ang II but only a modest response when administered alone ( Figure  2) . Similarly, full expression of the sulprostone-induced vasoconstriction required pretreatment with both Ang II and PGE 2 . We interpret these observations as suggesting that EP 3 receptor activation alone is not sufficient to cause vasoconstriction but rather promotes vasoconstriction by counteracting EP 4 signaling and reversing the PGE 2 -induced vasodilation. Thus, at low concentrations, PGE 2 stimulates EP 4 receptors, activates G ␣s and adenylyl cyclase, and elevates cAMP. At higher concentrations or under conditions in which the EP 3 receptor expression is upregulated, PGE 2 concurrently stimulates EP 3 receptors. EP 3 receptor activation inhibits adenylyl cyclase and decreases cAMP via G ␣i , thereby attenuating the EP 4 -mediated vasodilation. Activation of EP 3 receptors by PGE 2 and sulprostone have been shown to reduce cAMP-dependent water flux in the cortical collecting duct by a similar mechanism. 33 Thus, the EP 3 receptor pathway could provide a functional antagonism of the vasodepressant actions of PGE 2 . At the moment, one can only speculate on the potential significance of this interaction. However, it is important to note that although the preglomerular vasodepressor actions of PGE 2 are beneficial in maintaining adequate PGC during conditions of low renal perfusion pressure, this action may be detrimental when blood pressure is elevated, because myogenic vasoconstriction is also attenuated by PGE 2 (eg, see Reference 35) . Future studies assessing the impact of the EP 3 receptor on the reactivity of the afferent arteriole to PGE 2 and on the differential regulation of EP 3 and EP 4 receptor expression may provide insights into the physiological or pathophysiological importance of the afferent arteriolar EP 3 receptor.
In summary, the present study demonstrates that endogenous prostanoids and exogenous PGE 2 preferentially modulate the reactivity of the afferent arteriole. In this vessel, PGE 2 elicits a biphasic response, eliciting vasodilation at low concentrations (1 to 10 nmol/L) and reversing this effect at higher concentrations. The vasodilation is mediated by EP 4 receptors and is dependent on cAMP. The vasoconstriction is mediated by an EP 3 receptor and is blocked by PTX, implicating a mechanism dependent on G ␣i and reduced cAMP formation. These findings suggest a functional antagonism of these 2 receptor systems. We suggest that in the renal microvasculature, EP 3 receptors may play a modulatory role on the vasodepressant and renal hemodynamic actions of PGE 2 .
